Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes

European Journal of Haematology

Volumn 93, Issue 6, 2014, Pages 476-486

  Fei, Chengming ^a   Zhao, Youshan ^a   Guo, Juan ^a   Gu, Shucheng ^a   Li, Xiao ^a   Chang, Chunkang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Bone marrow mesenchymal stromal cells; Microenvironment; Myelodysplastic syndromes; P53 p21 pathway; Senescence

Indexed keywords

BETA GALACTOSIDASE; PROTEIN P21; PROTEIN P53; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE MARROW STROMA CELL; CANCER RISK; CD34 SELECTION; CELL AGING; CELL CYCLE ASSAY; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SIZE; CELL STRUCTURE; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STROMA CELL; MYELODYSPLASTIC SYNDROME; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; KARYOTYPE; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL AGING; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOSKELETON; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMANS; KARYOTYPE; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; OSTEOGENESIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84911409847     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12385     Document Type: Article

References (48)

1. Tauro S, Hepburn MD, Bowen DT, et al. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001;86:1038-45.
2. Ishibashi M, Tamura H, Ogata K. Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment. Leuk Res 2011;35:1449-52.
3. Raaijmakers MHGP. Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int J Hematol 2012;95:17-25.
4. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9.
5. Muguruma Y, Yahata T, Miyatake H, et al. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood 2006;107:1878-87.
6. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-36.
7. Klaus M, Stavroulaki E, Kastrinaki MC, et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev 2009;19:1043-54.
8. Flores-Figueroa E, Montesinos JJ, Flores-Guzmán P, et al. Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 2008;32:1407-16.
9. Zhao ZG, Xu W, Yu HP, et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett 2012;317:136-43.
10. Ferrer RA, Wobus M, List C, et al. Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica 2013;98:1677-85.
11. Song LX, Guo J, He Q, Yang LP, Gu SC, Zhang X, Wu LY, Li X, Chang CK. Bone marrow mesenchymal stem cells in myelodysplastic syndromes: cytogenetic characterization. Acta Haematol 2012;128:170-7.
12. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia 2009;23:664-72.
13. Blau O, Hofmann WK, Baldus CD, et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 2007;35:221-9.
14. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
15. Miura M, Miura Y, Padilla-Nash HM, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006;24:1095-103.
16. Geyh S, Öz S, Cadeddu RP, et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013;27:1841-51.
17. Campisi J, di Fagagna FA. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-40.
18. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 2008;3:e2213.
19. INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
20. Noh HB, Ahn HJ, Lee WJ, et al. The molecular signature of in vitro senescence in human mesenchymal stem cells. Genes Genomics 2010;32:87-93.
21. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-36.
22. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
23. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
24. Lemischka IR, Moore KA. Stem cells: interactive niches. Nature 2003;425:778-9.
25. Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829-34.
26. Shiozawa Y, Havens AM, Pienta KJ, et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008;22:941-50.
27. André T, Meuleman N, Stamatopoulos B, et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One 2013;8:e59756.
28. García-Castro J, Trigueros C, Madrenas J, et al. Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med 2008;12:2552-65.
29. Katsube Y, Hirose M, Nakamura C, et al. Correlation between proliferative activity and cellular thickness of human mesenchymal stem cells. Biochem Biophys Res Commun 2008;368:256-60.
30. McBeath R, Pirone DM, Nelson CM, et al. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 2004;6:483-95.
31. Nishio K, Inoue A. Senescence-associated alterations of cytoskeleton: extraordinary production of vimentin that anchors cytoplasmic p53 in senescent human fibroblasts. Histochem Cell Biol 2005;123:263-73.
32. Alexander K, Yang HS, Hinds PW. Cellular senescence requires CDK5 repression of Rac1 activity. Mol Cell Biol 2004;24:2808-19.
33. Gourlay CW, Ayscough KR. The actin cytoskeleton: a key regulator of apoptosis and ageing. Nat Rev Mol Cell Biol 2005;6:583-9.
34. Coppé JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118.
35. Davalos AR, Coppe JP, Campisi J, et al. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010;29:273-83.
36. Feng X, Scheinberg P, Wu CO, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011;96:602-6.
37. Kassem M, Marie PJ. Senescence-associated intrinsic mechanisms of osteoblast dysfunctions. Aging Cell 2011;10:191-7.
38. Zhao Z, Zhao M, Xiao G, et al. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 2005;12:247-53.
39. Wetzler M, Kurzrock R, Estrov Z, et al. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res 1995;19:23-34.
40. Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009;145:64-72.
41. Aggarwal S, van de Loosdrecht AA, Alhan C, et al. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011;153:568-81.
42. Lacey DC, Simmons PJ, Graves SE, et al. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage 2009;17:735-42.
43. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-22.
44. Gu Z, Jiang J, Tan W, et al. p53/p21 pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Clin Dev Immunol 2013;2013:134243.
45. Santamaría C, Muntión S, Rosón B, et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 2012;97:1218-24.
46. Yew TL, Chiu FY, Tsai CC, et al. Knockdown of p21Cip1/Waf1 enhances proliferation, the expression of stemness markers, and osteogenic potential in human mesenchymal stem cells. Aging Cell 2011;10:349-61.
47. Plasilova M, Schonmyer B, Fernandez J, et al. Accelerating stem cell proliferation by down-regulation of cell cycle regulator p21. Plast Reconstr Surg 2009;123(2S):149S-57S.
48. Tsai C-C, Chen Y-J, Yew T-L, et al. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011;117:459-69.